# Synbiotic Compound to Reduce Symptoms of Schizophrenia

> **NCT04226898** · PHASE2 · RECRUITING · sponsor: **Sheppard Pratt Health System** · enrollment: 68 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **BIOLOGICAL:** Synbiotic Supplement
- **BIOLOGICAL:** Inert Compound

## Key facts

- **NCT ID:** NCT04226898
- **Lead sponsor:** Sheppard Pratt Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-21
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226898, "Synbiotic Compound to Reduce Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04226898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*